Ann Hepatobiliary Pancreat Surg.  2023 May;27(2):123-130. 10.14701/ahbps.22-110.

Intrahepatic cholangiocarcinoma: Evolving role of neoadjuvant and targeted therapy

• Ghio M
• Vijay A

• KMID: 2542575
• DOI: http://doi.org/10.14701/ahbps.22-110

Abstract

Intrahepatic cholangiocarcinoma is an aggressive, often fatal, malignancy that arises from the bile ducts. As it often presents with metastatic disease, surgery has limited utility. However, in some cases, neoadjuvant chemotherapy has provided the necessary reduction in tumor burden to allow for adequate resection. Consequently, new advances in neoadjuvant chemoradiation and targeted therapy are of interest with numerous case reports and small series published routinely; it is challenging to present a large case series or study given the overall rare frequency with which this malignancy is seen. Herein, we aim to summarize the newest advances in both neoadjuvant chemotherapy and targeted immunotherapy.

Keyword

Cholangiocarcinoma; Neoadjuvant treatment; Targeted; Immunotherapy

Reference

1. Rizzo A, Brandi G. 2021; Neoadjuvant therapy for cholangiocarcinoma: a comprehensive literature review. Cancer Treat Res Commun. 27:100354. DOI: 10.1016/j.ctarc.2021.100354. PMID: 33756174.

2. Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. 2017; New horizons for precision medicine in biliary tract cancers. Cancer Discov. 7:943–962. DOI: 10.1158/2159-8290.CD-17-0245. PMID: 28818953. PMCID: PMC5586506.

3. Raufi AG, Manji GA, Chabot JA, Bates SE. 2019; Neoadjuvant treatment for pancreatic cancer. Semin Oncol. 46:19–27. DOI: 10.1053/j.seminoncol.2018.12.002. PMID: 30630600.

4. Jung JH, Lee HJ, Lee HS, Jo JH, Cho IR, Chung MJ, et al. 2017; Benefit of neoadjuvant concurrent chemoradiotherapy for locally advanced perihilar cholangiocarcinoma. World J Gastroenterol. 23:3301–3308. DOI: 10.3748/wjg.v23.i18.3301. PMID: 28566890. PMCID: PMC5434436.

5. Sumiyoshi T, Shima Y, Okabayashi T, Negoro Y, Shimada Y, Iwata J, et al. 2018; Chemoradiotherapy for initially unresectable locally advanced cholangiocarcinoma. World J Surg. 42:2910–2918. DOI: 10.1007/s00268-018-4558-1. PMID: 29511872.

6. Kato A, Shimizu H, Ohtsuka M, Yoshidome H, Yoshitomi H, Furukawa K, et al. 2013; Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study. Ann Surg Oncol. 20:318–324. DOI: 10.1245/s10434-012-2312-8. PMID: 23149849.

7. Stein A, Arnold D, Bridgewater J, Goldstein D, Jensen LH, Klümpen HJ, et al. 2015; Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. BMC Cancer. 15:564. DOI: 10.1186/s12885-015-1498-0. PMID: 26228433. PMCID: PMC4520064.

8. Nakachi K, Konishi M, Ikeda M, Mizusawa J, Eba J, Okusaka T, et al. 2018; A randomized Phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT). Jpn J Clin Oncol. 48:392–395. DOI: 10.1093/jjco/hyy004. PMID: 29462482.

9. Ibrahim SM, Mulcahy MF, Lewandowski RJ, Sato KT, Ryu RK, Masterson EJ, et al. 2008; Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer. 113:2119–2128. DOI: 10.1002/cncr.23818. PMID: 18759346.

10. Mouli S, Memon K, Baker T, Benson AB 3rd, Mulcahy MF, Gupta R, et al. 2013; Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol. 24:1227–1234. DOI: 10.1016/j.jvir.2013.02.031. PMID: 23602420. PMCID: PMC3800023.

11. Saxena A, Bester L, Chua TC, Chu FC, Morris DL. 2010; Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol. 17:484–491. DOI: 10.1245/s10434-009-0777-x. PMID: 19876691.

12. Edeline J, Touchefeu Y, Guiu B, Farge O, Tougeron D, Baumgaertner I, et al. 2020; Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 6:51–59. DOI: 10.1001/jamaoncol.2019.3702. PMID: 31670746. PMCID: PMC6824230.

13. Riby D, Mazzotta AD, Bergeat D, Verdure L, Sulpice L, Bourien H, et al. 2020; Downstaging with radioembolization or chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Ann Surg Oncol. 27:3729–3737. DOI: 10.1245/s10434-020-08486-7. PMID: 32472411.

14. Kato A, Shimizu H, Ohtsuka M, Yoshitomi H, Furukawa K, Takayashiki T, et al. 2015; Downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer patients treated with gemcitabine plus cisplatin combination therapy followed by radical surgery. Ann Surg Oncol. 22 Suppl 3:S1093–S1099. DOI: 10.1245/s10434-015-4768-9. PMID: 26240009.

15. Rayar M, Sulpice L, Edeline J, Garin E, Levi Sandri GB, Meunier B, et al. 2015; Intra-arterial yttrium-90 radioembolization combined with systemic chemotherapy is a promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment. Ann Surg Oncol. 22:3102–3108. DOI: 10.1245/s10434-014-4365-3. PMID: 25623598.

16. Le Roy B, Gelli M, Pittau G, Allard MA, Pereira B, Serji B, et al. 2018; Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Br J Surg. 105:839–847. DOI: 10.1002/bjs.10641. PMID: 28858392.

17. Kamarajah S, Giovinazzo F, Roberts KJ, Punia P, Sutcliffe RP, Marudanayagam R, et al. 2020; The role of down staging treatment in the management of locally advanced intrahepatic cholangiocarcinoma: review of literature and pooled analysis. Ann Hepatobiliary Pancreat Surg. 24:6–16. DOI: 10.14701/ahbps.2020.24.1.6. PMID: 32181423. PMCID: PMC7061034.

18. Lunsford KE, Javle M, Heyne K, Shroff RT, Abdel-Wahab R, Gupta N, et al. 2018; Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol. 3:337–348. Erratum in: Lancet Gastroenterol Hepatol 2018;3:e3. DOI: 10.1016/S2468-1253(18)30045-1. PMID: 29548617.

19. Moris D, Rahnemai-Azar AA, Zhang X, Ntanasis-Stathopoulos I, Tsilimigras DI, Chakedis J, et al. 2017; Program death-1 immune checkpoint and tumor microenvironment in malignant liver tumors. Surg Oncol. 26:423–430. DOI: 10.1016/j.suronc.2017.08.005. PMID: 29113661.

20. Ju JY, Dibbern ME, Mahadevan MS, Fan J, Kunk PR, Stelow EB. 2020; Mismatch repair protein deficiency/microsatellite instability is rare in cholangiocarcinomas and associated with distinctive morphologies. Am J Clin Pathol. 153:598–604. DOI: 10.1093/ajcp/aqz199. PMID: 31844887.

21. Gou M, Zhang Y, Liu T, Si H, Wang Z, Yan H, et al. 2021; PD-1 inhibitors could improve the efficacy of chemotherapy as first-line treatment in biliary tract cancers: a propensity score matching based analysis. Front Oncol. 11:648068. DOI: 10.3389/fonc.2021.648068. PMID: 34221968. PMCID: PMC8248534.

22. Zhang Z, Zhang W, Wang H, Hu B, Wang Z, Lu S. 2021; Successful treatment of advanced intrahepatic cholangiocarcinoma with a high tumor mutational burden and PD-L1 expression by PD-1 blockade combined with tyrosine kinase inhibitors: a case report. Front Immunol. 12:744571. DOI: 10.3389/fimmu.2021.744571. PMID: 34603331. PMCID: PMC8484748.

23. Rizzo A, Ricci AD, Brandi G. 2021; Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. Expert Opin Investig Drugs. 30:343–350. DOI: 10.1080/13543784.2021.1897102. PMID: 33645367.

24. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, et al. 2012; Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 17:72–79. DOI: 10.1634/theoncologist.2011-0386. PMID: 22180306. PMCID: PMC3267826.

25. Boscoe AN, Rolland C, Kelley RK. 2019; Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. J Gastrointest Oncol. 10:751–765. DOI: 10.21037/jgo.2019.03.10. PMID: 31392056. PMCID: PMC6657309.

26. Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. 2020; Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 21:796–807. Erratum in: Lancet Oncol 2020;21:e462. DOI: 10.1016/S1470-2045(20)30157-1. PMID: 32416072.

27. Graham RP, Barr Fritcher EG, Pestova E, Schulz J, Sitailo LA, Vasmatzis G, et al. 2014; Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol. 45:1630–1638. DOI: 10.1016/j.humpath.2014.03.014. PMID: 24837095.

28. Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. 2020; Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 21:671–684. DOI: 10.1016/S1470-2045(20)30109-1. PMID: 32203698.

29. Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, et al. 2018; Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol. 36:276–282. DOI: 10.1200/JCO.2017.75.5009. PMID: 29182496. PMCID: PMC6075847.

30. Ikeda M, Ioka T, Fukutomi A, Morizane C, Kasuga A, Takahashi H, et al. 2018; Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine. Cancer Sci. 109:215–224. DOI: 10.1111/cas.13438. PMID: 29121415. PMCID: PMC5765304.

31. Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, et al. 2011; Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 29:2357–2363. DOI: 10.1200/JCO.2010.33.9473. PMID: 21519026. PMCID: PMC3107751.

32. Subbiah V, Lassen U, Élez E, Italiano A, Curigliano G, Javle M, et al. 2020; Dabrafenib plus trametinib in patients with BRAF^V600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 21:1234–1243. DOI: 10.1016/S1470-2045(20)30321-1. PMID: 32818466.

33. Lavingia V, Fakih M. 2016; Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review. J Gastrointest Oncol. 7:E98–E102. DOI: 10.21037/jgo.2016.09.13. PMID: 28078132. PMCID: PMC5177579.

34. Churi CR, Shroff R, Wang Y, Rashid A, Kang HC, Weatherly J, et al. 2014; Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One. 9:e115383. DOI: 10.1371/journal.pone.0115383. PMID: 25536104. PMCID: PMC4275227.

35. Galdy S, Lamarca A, McNamara MG, Hubner RA, Cella CA, Fazio N, et al. 2017; HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? Cancer Metastasis Rev. 36:141–157. DOI: 10.1007/s10555-016-9645-x. PMID: 27981460. PMCID: PMC5385197.

36. Amin NEL, Hansen TF, Fernebro E, Ploen J, Eberhard J, Lindebjerg J, et al. 2021; Randomized Phase II trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable biliary tract cancer without KRAS exon 2 mutations. Int J Cancer. 149:119–126. DOI: 10.1002/ijc.33509. PMID: 33561312.

37. Golan T, Raitses-Gurevich M, Kelley RK, Bocobo AG, Borgida A, Shroff RT, et al. 2017; Overall survival and clinical characteristics of BRCA-associated cholangiocarcinoma: a multicenter retrospective study. Oncologist. 22:804–810. DOI: 10.1634/theoncologist.2016-0415. PMID: 28487467. PMCID: PMC5507643.

38. Fouassier L, Marzioni M, Afonso MB, Dooley S, Gaston K, Giannelli G, et al. 2019; Signalling networks in cholangiocarcinoma: molecular pathogenesis, targeted therapies and drug resistance. Liver Int. 39 Suppl 1:43–62. DOI: 10.1111/liv.14102. PMID: 30903728.

39. Isomoto H. 2009; Epigenetic alterations in cholangiocarcinoma-sustained IL-6/STAT3 signaling in cholangio- carcinoma due to SOCS3 epigenetic silencing. Digestion. 79 Suppl 1:2–8. DOI: 10.1159/000167859. PMID: 19153483.

40. Wang W, Zhong W, Yuan J, Yan C, Hu S, Tong Y, et al. 2015; Involvement of Wnt/β-catenin signaling in the mesenchymal stem cells promote metastatic growth and chemoresistance of cholangiocarcinoma. Oncotarget. 6:42276–42289. DOI: 10.18632/oncotarget.5514. PMID: 26474277. PMCID: PMC4747224.